EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism

Laura Girardi iD, Tzu-Fei Wang iD, Walter Ageno iD, Marc Carrier iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2023-06 · 43 (6) · 824-831

DOI: 10.1161/atvbaha.123.318779 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2023-06. Verfasst von Laura Girardi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Insubria, Varese, Italy (L.G., W.A.). Hauptthemen laut MEDLINE: Venous Thromboembolism, Neoplasms. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 75 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with cancer are at higher risk of developing venous thromboembolism (VTE) compared with the general population. This elevated risk is due to several risk factors and multiple, overlapping thrombotic and hemostatic pathophysiological pathways that are specific to this patient population. Hence, the management of cancer-associated VTE can be challenging for clinicians. Patients with cancer-associated VTE are at higher risk of both recurrent events despite anticoagulation and bleeding complications due to the anticoagulant regimens. Direct oral anticoagulants have recently been shown to be effective, safe, and more convenient than parenteral low-molecular-weight heparin for the management of cancer-associated VTE. Despite these recent advances in anticoagulant therapy, many unmet needs remain in these patients (increased risk of bleeding with specific cancer types, drug-drug interactions, liver dysfunction). Factor XI inhibitors are currently being assessed for the management of cancer-associated VTE and may help clinicians address these important knowledge gaps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismNeoplasmsHumansIncidenceAnticoagulantsHeparin, Low-Molecular-Weight

Stichwörter der Autor:innen

anticoagulantshemorrhageneoplasmsvenous thromboembolismvenous thrombosis

Substanzen

AnticoagulantsHeparin, Low-Molecular-Weight

Autor:innen und Institutionen

  • Department of Medicine and Surgery, University of Insubria, Varese, Italy (L.G., W.A.).
  • Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada (T.-F.W., M.C.).

ORCID-Profile: Laura Girardi, Tzu-Fei Wang, Walter Ageno, Marc Carrier

Zitieren

APA

Girardi, L., Wang, T. F., Ageno, W., & Carrier, M. (2023). Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 43(6), 824-831. https://doi.org/10.1161/atvbaha.123.318779

Vancouver

Girardi L, Wang TF, Ageno W, Carrier M. Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023;43(6):824-831. doi:10.1161/atvbaha.123.318779

BibTeX
@article{Girardi2023,
  author = {Girardi, Laura and Wang, Tzu-Fei and Ageno, Walter and Carrier, Marc},
  title = {Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2023},
  volume = {43},
  number = {6},
  pages = {824--831},
  doi = {10.1161/atvbaha.123.318779}
}
Kostenlos starten →